Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Harvard Business School
McKinsey
Baxter
Moodys

Last Updated: June 27, 2022

Cabotegravir sodium - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

What are the generic sources for cabotegravir sodium and what is the scope of freedom to operate?

Cabotegravir sodium is the generic ingredient in one branded drug marketed by Viiv Hlthcare and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Cabotegravir sodium has one hundred and nineteen patent family members in thirty-one countries.

One supplier is listed for this compound.

Summary for cabotegravir sodium
International Patents:119
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 14
Clinical Trials: 1
Patent Applications: 7
What excipients (inactive ingredients) are in cabotegravir sodium?cabotegravir sodium excipients list
DailyMed Link:cabotegravir sodium at DailyMed
Recent Clinical Trials for cabotegravir sodium

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
ViiV HealthcarePhase 1

See all cabotegravir sodium clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for cabotegravir sodium

US Patents and Regulatory Information for cabotegravir sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare VOCABRIA cabotegravir sodium TABLET;ORAL 212887-001 Jan 21, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Viiv Hlthcare VOCABRIA cabotegravir sodium TABLET;ORAL 212887-001 Jan 21, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Viiv Hlthcare VOCABRIA cabotegravir sodium TABLET;ORAL 212887-001 Jan 21, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Viiv Hlthcare VOCABRIA cabotegravir sodium TABLET;ORAL 212887-001 Jan 21, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for cabotegravir sodium

Country Patent Number Title Estimated Expiration
Australia 2006239177 Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity See Plans and Pricing
Mexico 2007013351 DERIVADO DE CARBAMOILPIRIDONA POLICICLICO QUE TIENE ACTIVIDAD INHIBIDORA DE LA INTEGRASA DE HIV. (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY.) See Plans and Pricing
South Korea 101363875 See Plans and Pricing
Spain 2906792 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2006088173 See Plans and Pricing
South Korea 101848819 See Plans and Pricing
Japan 2008540343 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for cabotegravir sodium

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1874117 CA 2014 00032 Denmark See Plans and Pricing PRODUCT NAME: DOLUTEGRAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, HERUNDER DOLUTEGRAVIRNATRIUM; REG. NO/DATE: EU/1/13/892/001-002 20140116
2465580 2021C/519 Belgium See Plans and Pricing PRODUCT NAME: VOCABRIA-CABOTEGRAVIR; AUTHORISATION NUMBER AND DATE: EU/1/20/1481 20201221
1874117 C01874117/01 Switzerland See Plans and Pricing PRODUCT NAME: DOLUTEGRAVIR; REGISTRATION NO/DATE: SWISSMEDIC 63052 08.05.2014
1874117 C20140020 00130 Estonia See Plans and Pricing PRODUCT NAME: DOLUTEGRAVIIR;REG NO/DATE: K(2014)305 (LOPLIK) 21.01.2014
1874117 CR 2014 00032 Denmark See Plans and Pricing PRODUCT NAME: DOLUTEGRAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, HERUNDER DOLUTEGRAVIRNATRIUM; REG. NO/DATE: EU/1/13/892/001-002 20140121
1874117 PA2014021,C1874117 Lithuania See Plans and Pricing PRODUCT NAME: DOLUTEGRAVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA ARBA SOLVATAS, ISKAITANT DOLUTEGRAVIRO NATRIO DRUSKA; REGISTRATION NO/DATE: EU/1/13/892/001, 2014-01-16 EU/1/13/892/002 20140116
2465580 PA2021512 Lithuania See Plans and Pricing PRODUCT NAME: KABOTEGRAVIRAS; REGISTRATION NO/DATE: EU/1/20/1481 20201217
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Dow
McKesson
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.